Der Diabetologe

, Volume 2, Issue 3, pp 233–242 | Cite as

Medikamentöse Therapie der Adipositas

Leitthema
  • 37 Downloads

Zusammenfassung

Die Adipositas ist eine schwer zu behandelnde Krankheit. Nicht nur Patienten, auch Ärzte unterschätzen häufig die Schwierigkeit, das Gewicht effektiv und dauerhaft zu senken. Liegen frustrane Therapieversuche mittels Lebensstiländerung vor, ist eine medikamentöse Behandlung indiziert. Diese muss mit potenten Antiadiposita fachkundig wie jede andere Behandlung durchgeführt werden. Dazu sind Kenntnisse des Wirkmechanismus, der Auswirkungen auf das Gewicht und weitere Stoffwechselparameter sowie der Nebenwirkungen erforderlich.

Schlüsselwörter

Adipositas Gewichtsabnahme Pharmaka Morbidität Risikofaktoren 

Medical treatment of obesity

Abstract

Obesity is a difficult disease to treat. Not only patients, but also doctors often underestimate the difficulties involved in achieving efficient and long-lasting body weight reduction. Pharmacological treatment is indicated when attempts at treatment based on lifestyle changes have remained unsuccessful. Like any other drug treatment, the administration of potent anti-obesity drugs has to be carried out in an informed and competent manner. This means that knowledge of each drug’s mechanism of action, effects on body weight, other metabolic aspects and side effects is mandatory.

Keywords

Obesity Weight reduction Pharmaceutical preparations Morbidity Risk factors 

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Der Autor tritt bei Veranstaltungen auf, die von den Firmen Sanofi-Aventis, Abbott und Hoffmann-La Roche finanziell unterstützt werden.

Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Literatur

  1. 1.
    Anderson JW, Konz EC, Frederich RC et al. (2001) Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579–584PubMedGoogle Scholar
  2. 2.
    Chiasson JL, Josse RG, Gomis R et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486–494CrossRefPubMedGoogle Scholar
  3. 3.
    DeFronzo RA, Ratner RE, Han J et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100PubMedGoogle Scholar
  4. 4.
    Després JP, Golay A, Sjöström L for the Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121–2134CrossRefPubMedGoogle Scholar
  5. 5.
    Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403PubMedGoogle Scholar
  6. 6.
    Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev 3: 771–784Google Scholar
  7. 7.
    Heal DJ, Prow MR, Jackson HC et al. (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes [Suppl 1] 22: S18–S28Google Scholar
  8. 8.
    Hollander PA, Elbein SC, Hirsch IB et al. (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21: 1288–1294PubMedGoogle Scholar
  9. 9.
    James WPh, Astrup A, Hilsted J et al. for the STORM Group (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356: 2119–2125CrossRefPubMedGoogle Scholar
  10. 10.
    Lean MEJ (1997) Sibutramine – a review of clinical efficacy. Int J Obes 21: 116–123Google Scholar
  11. 10a.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. for the RIO-North-America-Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight patients. RIO-North-America: A randomized controlled trial. JAMA 295: 761–775CrossRefPubMedGoogle Scholar
  12. 11.
    Scholze J (2002) Adipositasbehandlung mit Sibutramin unter Praxisbedingungen. Dtsch Med Wochenschr 127: 606–610CrossRefPubMedGoogle Scholar
  13. 12.
    Sharma AM, Golay A (2002) Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 20: 1873–1878CrossRefPubMedGoogle Scholar
  14. 13.
    Sjöström L, Rissanen A, Andersen T et al. for the European Multicentre Study Group (1998) Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167–173CrossRefPubMedGoogle Scholar
  15. 14.
    Sjöström L, Lindroos AK, Peltonen M et al. for the Swedish Obese Subjects Study Scientific Group (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683–2693CrossRefPubMedGoogle Scholar
  16. 15.
    Torgerson JS, Boldrin MN, Hauptmann J et al., XENical in the Prevention of Diabetes in the Obese Subjects (XENDOS) Study (2004) A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese subjects. Diabetes Care 27: 155–161PubMedGoogle Scholar
  17. 16.
    Van Gaal LF, Wauters MA, Pfeiffer FW et al. (1998) Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes [Suppl 1] 22: S38–S40Google Scholar
  18. 17.
    Van Gaal L, Rissanen AM, Scheen A et al. for the RIO-Europe-Study Group (2005) Effects fo the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389–1397CrossRefPubMedGoogle Scholar
  19. 18.
    Wirth A (2004) Reduction of body weight and co-morbidities by orlistat: the XXL-primary health care trial. Diabetes Obes Metab 7: 21–27CrossRefGoogle Scholar
  20. 19.
    Wirth A, KrauseJ (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 1331–1339CrossRefPubMedGoogle Scholar
  21. 20.
    Wirth A, Scholze J, Sharma AM et al. (in press) Reduced left ventricular mass after treatment of obese patients with sibutramine: an echocardiographic multicentre study. Diabetes Obes Metab in pressGoogle Scholar
  22. 21.
    World Health Organization (2000) Obesity. Preventing and managing the global epidemic. WHO, Genf, p 276Google Scholar
  23. 22.
    Zhi J, Melia AT, Guerciolini R et al. (1994) Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56: 82–85PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Teutoburger-Wald-KlinikBad Rothenfelde

Personalised recommendations